TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04735887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SADL-eM
Description: The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
Study: NCT05586646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alanyl-glutamine
Description: Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
Study: NCT04602585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education
Description: Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-education
Description: Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
Study: NCT05882188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Description: oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ExEm Foam
Description: ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
Study: NCT05186285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study: NCT06295536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator device, Closed-field autorefractometer
Description: * Objective refraction without cycloplegia~* Distance visual acuity with objective refraction without cycloplegia~* Objective refraction with cycloplegia~* Distance visual acuity with objective refraction with cycloplegia
Study: NCT05570877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChitoCare medical Wound Healing Gel
Description: ChitoCare medical Wound Healing Gel is a CE-marked medical device.
Study: NCT06557317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Girls for Wellness In-Person
Description: Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
Study: NCT05839587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic TAPP
Description: Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP
Description: Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
Study: NCT04383158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)
Description: ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
Study: NCT05024604

Intervention type: DRUG
Intervention: Progesterone Only Product in Oral Dose Form
Description: mini pills as a contraceptive method

Intervention type: OTHER
Intervention: office hysterscopy
Description: office hysteroscoy

Intervention type: OTHER
Intervention: office hysterscopy
Description: office hysteroscoy
Study: NCT05581966

Intervention type: DIAGNOSTIC_TEST
Intervention: DV-SSP Imaging
Description: DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
Study: NCT04955132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
Study: NCT05096728

Intervention type: DRUG
Intervention: Nifedipine XL
Description: Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg

Intervention type: DRUG
Intervention: Nifedipine XL
Description: Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg
Study: NCT04992910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation through medical device
Description: The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
Study: NCT05046184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam injection
Description: Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
Study: NCT04721392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental fatigue (Stroop task)
Description: A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental fatigue (Stroop task)
Description: A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (documentary)
Description: In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (documentary)
Description: In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
Study: NCT03636165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The local infiltration solution containing 2mg Ropivacaine per milliliter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The local infiltration solution containing 2mg Ropivacaine per milliliter.
Study: NCT05238779

Intervention type: OTHER
Intervention: Standard of care including palliative care
Description: Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
Study: NCT05113290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5 injection
Description: Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
Study: NCT05896761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
Study: NCT05113290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
Study: NCT05896761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study: NCT05384678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (54 mg)
Description: A dose rate of 0.6 mg/min will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (108 mg)
Description: A dose rate of 1.2 mg/min will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (162 mg)
Description: A dose rate of 1.8 mg/min will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (216 mg)
Description: A dose rate of 2.4 mg/min will be administered
Study: NCT05939726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturising cream with vitamin E concentrate
Description: The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturising cream without vitamin E concentrate
Description: This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urea cream
Description: Urea cream (10%w/w) is used as the standard of care for PPE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urea cream
Description: Urea cream (10%w/w) is used as the standard of care for PPE.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urea cream
Description: Urea cream (10%w/w) is used as the standard of care for PPE.
Study: NCT05377125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized placebo training
Description: This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
Study: NCT06433895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation
Study: NCT06461156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10504
Description: HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
Study: NCT04660370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT04767958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 Platform
Description: Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 Platform
Description: Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
Study: NCT04639791

Intervention type: OTHER
Intervention: No intervention
Description: Observation only, no intervention
Study: NCT05384678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo (saline infusion) will be administered.
Study: NCT05478928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic dry needling
Description: An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed dose dynamic MEP
Description: Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Dry needling
Description: An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed dose static MEP
Description: Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm-based dose static MEP
Description: Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
Study: NCT05384678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (108 mg) + dose titration
Description: A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
Study: NCT05478928

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
Study: NCT04743817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OtoSet - Ear Cleaning System
Description: Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
Study: NCT06073886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active cTBS
Description: 600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: 600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive/Sham cTBS
Description: 600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal exposure
Description: Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Description: Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Imaginal exposure
Description: Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
Study: NCT05353361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811：Pyrotinib
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；Pertuzumab
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；Adebrelimab
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；Albumin paclitaxel
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip